Released Feb 28, 2023, after the close
10-K filed Feb 28, 2023, 59 days after period end · 0000950170-23-005067
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$44.36M$44.36M derived+159.9% vs Q4 2021+196.1% vs Q3 2022
Net Income-$56.36M-$56.36M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$64,419,000N/M
Operating Cash Flowderived-$75,389,000N/M
Free Cash Flowderived-$82,066,000N/M
Margins · derived
Operating margin-145.2%+261.3 pt vs Q4 2021
Net margin-127.1%+275.0 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $44.36M | $17.07M | $15.90M | $2.80M |
| Net Income | -$56.36M | -$68.62M | -$53.11M | -$28.30M |
| EPS Diluted | — | — | — | -$0.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR